A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma (GENHIV)

• ClinicalTrials.gov Identifier: NCT03593187
• Recruitment Status: Completed
• First Posted: July 20, 2018
• Last Update Posted: November 7, 2022
• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: CSL Behring
• Information provided by (Responsible Party): Assistance Publique - Hôpitaux de Paris

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety and the feasibility, and the success of engraftment of the introduction of Cal-1 gene-transduced haematopoietic cell populations (Ttn and HSPCtn) in patients with HIV-1-related high-risk lymphoma.

Condition or disease	Intervention/treatment	Phase
HIV-1 Infection	Drug: Cal-1 (LVsh5/C46) drug product	Phase 1; Phase 2

Detailed Description:

not provided

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 2 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II Study of the Safety of CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, in HIV-1 Infected Patients With High-risk Lymphoma
• Actual Study Start Date: January 15, 2019
• Actual Primary Completion Date: July 28, 2020
• Actual Study Completion Date: July 28, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cal-1( LVsh5/C46) drug product	Drug: Cal-1 (LVsh5/C46) drug product; Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct

Outcome Measures

Primary Outcome Measures :

1. Incidence of adverse event post transplant [ Time Frame: 24 months post-transplant ]
   to evaluate the procedure safety
2. Success of hematopoietic stem cell engraftment [ Time Frame: 24 months post-transplant ]
   evaluation of Cal-1 marking and expression in peripheral blood subpopulations (monocytes, CD4+ and CD8+ lymphocytes)

Secondary Outcome Measures :

1. Overall survival [ Time Frame: 24 months post-transplant ]
2. Absence of detection of vector-derived Replication competent lentivirus (RCL) [ Time Frame: 24 months post-transplant ]
3. Frequency and severity of clinical adverse events [ Time Frame: 24 months post-transplant ]
   as assessed by the United States national Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
4. Absence of tropism shift from R5 to dual/mixed or X4 at any point after Day 0 [ Time Frame: 24 months post-transplant ]
5. Quantify gene transfer efficiency and expression [ Time Frame: 24 months post-transplant ]
   extent of HSPCtn and Ttn survival as measured by Cal-1 marking and expression in peripheral blood
6. Time to restart antiretroviral therapy [ Time Frame: 24 months post-transplant ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Eligible subjects will undergo screening assessments at three time points:

• Screening 1 at the beginning of chemotherapy,
• Screening 2 (first "check-point") after the harvest for CD34,
• Screening 3 (second "check-point") before the ASCT procedure. Potential subjects must satisfy all of the inclusion criteria to be enrolled in the study and proceed with the first apheresis (day -39).

In-A. Prior to any study-related procedures, signed informed consent indicating that they understand the purpose, risks and procedures required for the study and are willing to participate in the study In-B. Individuals aged 18 to 60 years of age (inclusive) at time of consent In-C. Women with child-bearing potential must be on adequate effective contraception (continuous progestative contraception) In-D. Documented HIV-1 infection at or before the time of lymphoma diagnosis In-E. Treatment with antiretroviral agents (excluding NNRTI) introduced or optimized at the time of screening

In-F. Biopsy-proven lymphoma meeting one of the following criteria:

1. 1. Intermediate- or high-grade B-cell non-Hodgkin lymphoma, meeting 1 of the following criteria:

   • in first complete remission with high-risk features such as T-cell lymphoma and plasmablastic lymphoma (after multidisciplinary consultation regarding the indication of ASCT in this context). The decision of ASCT is independent of the present clinical trial.
   • in partial remission
   • relapsed after initial complete remission
   • failed induction therapy but responds to salvage therapy (i.e., chemosensitive disease)

2. Hodgkin lymphoma, meeting 1 of the following criteria:

   • in first or greater relapse after initial complete remission
   • in partial remission
   • failed induction therapy but responds to salvage therapy (i.e. chemosensitive disease)
3. High-risk lymphoma requiring a treatment with combined chemotherapy and autologous stem cell transplantation (ASCT)

Exclusion Criteria:

Ex-A. -Left ventricular ejection fraction <50% at Screening 1:

Ex-B. Abnormal biochemistry at Screening 1:

Alanine and/or aspartate aminotransferase (ALT/AST) >10 x upper limit of normal (ULN) Total bilirubin > 2.5 x ULN Creatinine clearance <60ml/min Ex-C. Severe coagulopathy Ex-D. Prothombin time > 2x ULN Ex-E. Evidence of co-infection with hepatitis B virus (HBsAg+), hepatitis C virus, West Nile Virus, or Human T-lymphotropic virus (HTLV-1) as detected at Screening 1 Ex-F. Stay in West Nile Virus endemic area less than 6 weeks prior to CD34+ collection Ex-G. Evidence of non-treated opportunistic infection during the pre-infusion period Ex-H. Evidence of not-treated CNS involvement of lymphoma at Screening 1 Ex-I. Isolated CNS relapse of the lymphoma without other evidence of active disease at Screening 1 Ex-J. Known hypersensitivity to G-CSF (Neupogen™) or plerixafor (Mozobil™) Ex-K. Evidence of uncontrolled HIV-1 viremia at screening 2 and/or 3 (plasma HIV-1 RNA ≥ 1.000 copies/ml confirmed in 2 successive blood samples) Ex-L. Evidence of chemoresistant lymphoma at screening 2 Ex-M. Any contra-indication to ASCT at any time during the pre-infusion period Ex-N. Participation in any study involving any investigational drug or medical device within 3 months prior to Screening 1 Ex-O. Receipt of a vaccine for HIV-1 or any gene transfer product at any time Ex-P. Subjects who will not accept transfusions of blood products Ex-Q. Pregnant or breast-feeding woman at any time Ex-R. Woman of child-bearing potential not under adequate contraceptive protection at any time Ex-S. Inability to understand and provide informed consent Psychological or psychiatric disability thought to be clinically significant in the opinion of the investigator

Contacts and Locations

Locations

France

Hôpital Saint Louis

Paris, France, 75475

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

CSL Behring

Investigators

• Study Chair: Marina CAVAZZANA, MD, PhD; Assistance Publique - Hôpitaux de Paris
• Principal Investigator: Eric OKSENHENDLER, MD, PhD; Assistance Publique - Hôpitaux de Paris

More Information

• Responsible Party: Assistance Publique - Hôpitaux de Paris
• ClinicalTrials.gov Identifier: NCT03593187
• Other Study ID Numbers: P 141004; 2015-004453-41 ( EudraCT Number )
• First Posted: July 20, 2018
• Last Update Posted: November 7, 2022
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Assistance Publique - Hôpitaux de Paris:

HIV-1; Lymphoma; Gene therapy

Additional relevant MeSH terms:

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases